Skip to main content
Terug
AHICF logo

Asahi Intecc Co., Ltd.

Datakwaliteit: 100%
Overbought
AHICF
OTC Healthcare Medical - Instruments & Supplies
€ 20,37
€ 0,00 (0,00%)
Marktkapitalisatie: 5,40B
Dagbereik
€ 17,95 € 20,37
52-Weeksbereik
€ 15,08 € 21,08
Volume
50
50D / 200D Gem.
€ 19,28 / € 17,74
Vorige Slotkoers
€ 20,37

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,4 0,4
P/B 0,0 2,9
ROE % 8,4 3,9
Net Margin % 10,6 3,8
Rev Growth 5Y % 18,2 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,00
€ 0,92 – € 1,06
 190 B 1
FY2029 € 0,89
€ 0,82 – € 0,95
 170 B 1
FY2028 € 0,84
€ 0,78 – € 0,89
 160 B 1

Belangrijkste Punten

Revenue grew 18,19% annually over 5 years — strong growth
Earnings declined -19,43% over the past year
Debt/Equity of 0,07 — conservative balance sheet
Generating 31,97B in free cash flow
P/E of 0,42 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,59%

Groei

Revenue Growth (5Y)
18,19%
Revenue (1Y)11,60%
Earnings (1Y)-19,43%
FCF Growth (3Y)123,05%

Kwaliteit

Return on Equity
8,44%
ROIC13,96%
Net Margin10,61%
Op. Margin25,06%

Veiligheid

Debt / Equity
0,07
Current Ratio3,71
Interest Coverage140,56

Waardering

P/E Ratio
0,42
P/B Ratio0,04
EV/EBITDA-1,25
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11,60% Revenue Growth (3Y) 15,42%
Earnings Growth (1Y) -19,43% Earnings Growth (3Y) -1,42%
Revenue Growth (5Y) 18,19% Earnings Growth (5Y) 6,28%
Profitability
Revenue (TTM) 120,03B Net Income (TTM) 12,74B
ROE 8,44% ROA 6,59%
Gross Margin 67,68% Operating Margin 25,06%
Net Margin 10,61% Free Cash Flow (TTM) 31,97B
ROIC 13,96% FCF Growth (3Y) 123,05%
Safety
Debt / Equity 0,07 Current Ratio 3,71
Interest Coverage 140,56 Dividend Yield 0,01%
Valuation
P/E Ratio 0,42 P/B Ratio 0,04
P/S Ratio 0,05 PEG Ratio -2,56
EV/EBITDA -1,25 Dividend Yield 0,01%
Market Cap 5,40B Enterprise Value -37,70B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 120,03B 107,55B 90,10B 77,75B 61,51B
Net Income 12,74B 15,81B 13,11B 10,86B 9,98B
EPS (Diluted) 46,92 58,20 48,25 40,00 38,07
Gross Profit 81,24B 69,05B 58,83B 51,08B 41,47B
Operating Income 30,08B 22,14B 18,03B 15,24B 12,80B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 193,19B 191,61B 172,64B 155,13B 115,43B
Total Liabilities 41,84B 39,66B 38,35B 34,00B 22,49B
Shareholders' Equity 150,56B 151,21B 132,31B 119,46B 92,91B
Total Debt 11,10B 6,70B 14,25B 12,18B 8,04B
Cash & Equivalents 54,20B 35,66B 34,88B 32,32B 21,36B
Current Assets 103,36B 94,70B 90,26B 79,61B 61,13B
Current Liabilities 27,86B 29,49B 26,32B 20,76B 14,67B

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#161 of 1052
65
Custom Deep Value Investing (Seth Klarman)
#366 of 827
45
Growth Price/Sales Ratio Focus (Ken Fisher)
#451 of 618
20
Value Defensive Investing (Benjamin Graham)
#529 of 709
15

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026